| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7893101 | AMGEN INC | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
Dec, 2023
(2 months from now) | |
| US7427638 | AMGEN INC | (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof |
Feb, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6962940 | AMGEN INC | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
Mar, 2023
(6 months ago) | |
| US7208516 | AMGEN INC | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
Mar, 2023
(6 months ago) | |
| US7659302 | AMGEN INC | Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione |
Mar, 2023
(6 months ago) | |
| US8455536 | AMGEN INC | Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione |
Mar, 2023
(6 months ago) | |
| US9018243 | AMGEN INC | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
Mar, 2023
(6 months ago) | |
| US8802717 | AMGEN INC | Methods of treating arthritic conditions using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione |
Mar, 2023
(6 months ago) | |
| US9724330 | AMGEN INC | Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
Mar, 2023
(6 months ago) | |
| US10092541 | AMGEN INC | Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast |
May, 2034
(10 years from now) | |
| US9872854 | AMGEN INC | Methods for the treatment of psoriatic arthritis using apremilast |
May, 2034
(10 years from now) | |
Otezla is owned by Amgen Inc.
Otezla contains Apremilast.
Otezla has a total of 11 drug patents out of which 7 drug patents have expired.
Expired drug patents of Otezla are:
- US6962940
- US7208516
- US7659302
- US8455536
- US9018243
- US8802717
- US9724330
Otezla was authorised for market use on 21 March, 2014.
Otezla is available in tablet;oral dosage forms.
Otezla can be used as use of otezla (apremilast) for inhibiting pde4; treatment of adult patients with oral ulcers associated with behcet's disease; treatment of adult patients with active psoriatic arthritis; treatment of patients with plaque psoriasis who are candidates for phototherapy or systemic therapy, use of otezla (apremilast) for the treatment of psoriasis; use of otezla (apremilast) for the treatment of psoriatic arthritis; treatment of adult patients with active psoriatic arthritis; treatment of adult patients with oral ulcers associated with behcet's disease; treatment of patients with plaque psoriasis who are candidates for phototherapy or systemic therapy, treatment of psoriasis using a dosage titration schedule; treatment of adult patients with oral ulcers associated with behcet's disease using a dosage titration schedule, treatment of psoriatic arthritis using a dosage titration schedule; treatment of psoriatic arthritis with apremilast using a dosage titration schedule and a second active agent, use of otezla (apremilast) for the treatment of psoriatic arthritis, use of otezla (apremilast) for the treatment of psoriasis; use of otezla (apremilast) for the treatment of psoriatic arthritis; treatment of adult patients with oral ulcers associated with behcet's disease; treatment of patients with plaque psoriasis who are candidates for phototherapy or systemic therapy, use of otezla (apremilast) for the treatment of psoriasis; use of otezla (apremilast) for the treatment of psoriatic arthritis; treatment of adult patients with oral ulcers associated with behcet's disease; treatment of adult patients with active psoriatic arthritis; treatment of patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.
The generics of Otezla are possible to be released after 29 May, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jul 19, 2026 |
| M (M) | Jul 20, 2026 |
| New Indication (I) | Dec 20, 2024 |
Drugs and Companies using APREMILAST ingredient
Market Authorisation Date: 21 March, 2014
Treatment: Use of otezla (apremilast) for inhibiting pde4; Treatment of adult patients with oral ulcers associated with behcet's disease; Treatment of adult patients with active psoriatic arthritis; Treatment of...
Dosage: TABLET;ORAL
OTEZLA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic